
NASDAQConsumer DefensivePackaged Foods
Latest quote
$1.14
−$0.005 · -0.44%
Natural Alternatives International, Inc. (NAII) is a company dedicated to the global development, manufacturing, and marketing of nutritional supplements, with operations spanning the United States, Europe, Asia, and other international territories. The company functions through two main divisions: Private-Label Contract Manufacturing and Patent and Trademark Licensing. Through its contract manufacturing segment, NAII provides tailored production services to businesses that market and distribute a range of health-related products, including vitamins, minerals, herbal remedies, and other dietary supplements. NAII also offers extensive strategic partnering support, which encompasses a broad spectrum of services. These include research and development (such as customized product formulation, scientific research, and proprietary ingredients), clinical studies, manufacturing, marketing assistance, adherence to international regulatory and labeling laws, global product registration, diverse packaging and labeling design, product testing, evaluation, and overall regulatory review. Furthermore, the company markets its own proprietary beta-alanine ingredient, available under the brand names CarnoSyn and SR CarnoSyn. NAII produces its supplements in various formats, including capsules, tablets, chewable wafers, and powders. Its private-label manufacturing clients primarily consist of companies distributing nutritional supplements through direct sales networks, direct-to-consumer e-commerce platforms, and traditional retail stores. Natural Alternatives International, Inc. was established in 1980 and is based in Carlsbad, California.
Previous close
$1.14
−$0.005 · -0.44%
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
55
Mixed
Risk
57
Elevated Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Natural Alternatives International, Inc. (NAII) is a company dedicated to the global development, manufacturing, and marketing of nutritional supplements, with operations spanning the United States, Europe, Asia, and other international territories. The company functions through two main divisions: Private-Label Contract Manufacturing and Patent and Trademark Licensing. Through its contract manufacturing segment, NAII provides tailored production services to businesses that market and distribute a range of health-related products, including vitamins, minerals, herbal remedies, and other dietary supplements. NAII also offers extensive strategic partnering support, which encompasses a broad spectrum of services. These include research and development (such as customized product formulation, scientific research, and proprietary ingredients), clinical studies, manufacturing, marketing assistance, adherence to international regulatory and labeling laws, global product registration, diverse packaging and labeling design, product testing, evaluation, and overall regulatory review. Furthermore, the company markets its own proprietary beta-alanine ingredient, available under the brand names CarnoSyn and SR CarnoSyn. NAII produces its supplements in various formats, including capsules, tablets, chewable wafers, and powders. Its private-label manufacturing clients primarily consist of companies distributing nutritional supplements through direct sales networks, direct-to-consumer e-commerce platforms, and traditional retail stores. Natural Alternatives International, Inc. was established in 1980 and is based in Carlsbad, California.
Day range
Current $1.14
52-week range
Current $1.14
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 141.35M USD | 129.86M USD | 113.8M USD | 154.02M USD | 170.97M USD |
| Cost of goods sold | 133.52M USD | 120.57M USD | 106.93M USD | 135.86M USD | 140.46M USD |
| Gross profit | 7.84M USD | 9.29M USD | 6.87M USD | 18.16M USD | 30.51M USD |
| Research and development | 2.3M USD | 1.8M USD | 1.9M USD | 2.1M USD | 2.5M USD |
| Selling, general, and administrative | 17.3M USD | 16.55M USD | 15.4M USD | 14.87M USD | 16.95M USD |
| Operating expenses | 16.9M USD | 17.95M USD | 15.4M USD | 13.45M USD | 16.83M USD |
| Interest income | 50K USD | 168K USD | 176K USD | 33K USD | — |
| Interest expense | 1.19M USD | 915K USD | 361K USD | 451K USD | 83K USD |
| Depreciation and amortization | 4.71M USD | 4.56M USD | 4.65M USD | 4.25M USD | 4.17M USD |
| Operating income | −9.06M USD | −8.66M USD | −8.53M USD | 4.71M USD | 13.68M USD |
| Net income | −20.7M USD | −13.58M USD | −7.22M USD | 2.52M USD | 10.71M USD |
Company facts updated Oct 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.